Sun Pharmaceutical Industries Limited announced top-line results from Phase 2 clinical trials evaluating SCD-044 for moderate to severe psoriasis.
The study, involving 263 participants, did not meet its primary endpoint of achieving a 75% improvement in PASI score at Week 16.
Sun Pharma is also discontinuing studies of SCD-044 for atopic dermatitis after Phase 2 trial results did not meet the primary objective of a 75% improvement in EASI score at Week 16. This study included 250 people.
According to Marek Honczarenko, MD, PhD, Senior Vice President and Head of Global Specialty Development at Sun Pharma, the company is disappointed with the top-line results but thanks all participants.
There were no major safety or tolerability concerns with SCD-044 in either study.
Sun Pharma and Sun Pharma Advanced Research Company Ltd. will evaluate the next steps for SCD-044; however, Sun Pharma has no further plans for development of SCD-044.